Home › Funds › Qube Research & Technologies Ltd › ALNY
Qube Research & Technologies Ltd position in ALNY
ALNYLAM PHARMACEUTICALS INC · Health Care
Qube Research & Technologies Ltd reported holding 798,715 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$240.4M, representing 0.47% of its reported portfolio and ranking #28 among its reported holdings. Qube Research & Technologies Ltd has disclosed ALNY holdings in 10 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Qube Research & Technologies Ltd's ALNY position evolved
Qube Research & Technologies Ltd first disclosed a stake in ALNY in Q3 2023 at 1,000 shares (US$177K). The position peaked in Q3 2025 at 811,278 shares, worth US$369.9M. Across 10 filings, Qube Research & Technologies Ltd increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 798,715 shares valued at US$240.4M — a reduction of -39,472 shares quarter over quarter.. Notable position changes include a 1745% increase in Q4 2023 (shares fell 22% over the following quarter), a 500% increase in Q1 2024 (shares rose 63% over the following quarter), a 50% trim in Q4 2024 (shares rose 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.00K | $177.10K | New |
| Q4 2023 | 18.45K | $3.53M | Add |
| Q1 2024 | 110.76K | $16.55M | Add |
| Q3 2024 | 200 | $55.01K | New |
| Q4 2024 | 100 | $23.53K | Reduce |
| Q1 2025 | 100 | $27.00K | Hold |
| Q3 2025 | 811.28K | $369.94M | New |
| Q4 2025 | 774.68K | $308.05M | Reduce |
| Q1 2026 | 838.19K | $277.33M | Add |
| Q2 2026 | 798.72K | $240.44M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALNY and 13F data
ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 35 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$734.5M), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALNY
- T. Rowe Price Investment Management, Inc. 5.64M sh · $1.70B · Q2 2026
- Baillie Gifford & Co 2.44M sh · $734.48M · Q2 2026
- Orbis Allan Gray Ltd 1.99M sh · $598.27M · Q2 2026
- Two Sigma Investments 1.88M sh · $564.71M · Q2 2026
- AMERICAN CENTURY COMPANIES INC 1.85M sh · $558.10M · Q2 2026
- TWO SIGMA ADVISERS, LP 1.13M sh · $450.36M · Q4 2025
- Deep Track Capital, LP 825.00K sh · $248.35M · Q2 2026
- LOS ANGELES CAPITAL MANAGEMENT LLC 729.63K sh · $219.64M · Q2 2026
- LOOMIS SAYLES & CO L P 580.19K sh · $174.65M · Q2 2026
More on Qube Research & Technologies Ltd
FAQ
How long has Qube Research & Technologies Ltd held ALNY?
Qube Research & Technologies Ltd has disclosed ALNY holdings in 10 of the last 12 reported quarters, going back to Q3 2023.
What is Qube Research & Technologies Ltd's current position in ALNY?
As of Q2 2026, Qube Research & Technologies Ltd holds 798.72K shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $240.44M, representing 0.47% of its reported portfolio and ranking #28.
Has Qube Research & Technologies Ltd been buying or selling ALNY?
In the latest 13F filing (Q2 2026), Qube Research & Technologies Ltd reduced its position in ALNY. The position peaked in Q3 2025 at 811.28K shares.
Which other funds hold ALNY?
Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.